AZD6738, Savolitinib, Ceralasertib, DURVALUMAB, Monalizumab, DOCETAXEL, AZD6738, Oleclumab clinical trials

Precision Immuno-Oncology for advanced Non-small cell lung cancer patients with PD-1 ICI Resistance (PIONeeR clinical study)

This study is for adults with a type of advanced lung cancer (non-small cell lung cancer) that has stopped responding to previous immune-boosting treatments. It's testing new combinations of medicines to see if they can help control the cancer, looking at how many people's cancer stops growing or shrinks after 12 weeks.